YAP1 and diffuse large B-cell lymphoma: In vitro (human DLBCL cell lines: LY1, LY8, LY3, and Val) and in vivo experimentations (on 5 week old female beige mice with severe combined immunodeficiency) demonstrated that the reduction in YAP presence with a CRISPR/Cas9 genome-editing system considerably contained tumor progression.